Annibale B, Marignani M, Azzoni C, D'Ambra G, Caruana P, D'Adda T, Delle Fave G, Bordi C
Gastroenterology Unit, University La Sapienza Rome, Italy.
Helicobacter. 1997 Jun;2(2):57-64. doi: 10.1111/j.1523-5378.1997.tb00060.x.
Usually, atrophic body gastritis has been considered an autoimmune disease characterized by the presence of parietal cell antibodies. Previous investigations into the role of Helicobacter pylori infection have obtained conflicting results. The aim of this study was to investigate the prevalence and role of H. pylori in a prospectively investigated population of patients with corpus-predominant atrophic gastritis.
A consecutive series of 67 newly diagnosed cases of atrophic body gastritis was derived from a screening of 326 patients with unexplained anemia or dyspepsia. Criteria for diagnosis were fasting hypergastrinemia, pentagastrin-resistant achlorhydria, and histological confirmation of body atrophy. In all 67 patients, H. pylori infection was evaluated independently by histological assay and urease test. The gastritis status of both the fundic and antral mucosa were graded according to the Sydney system. Parietal cell and intrinsic factor antibodies also were determined.
Active H. pylori infection was present in 26.8% of our patients and allowed us to identify a patient's subpopulation with a significantly smaller degree of body mucosa damage as shown by functional parameters (gastrin, gastric acid secretion, pepsinogen I) and histological assessment. In this subpopulation, a higher prevalence of gastric cancer familial history was found. Presence of parietal cell antibodies showed a similar prevalence in H. pylori-positive and H. pylori-negative patients (61.1% vs. 69.4%) and was not associated with significant functional and histological differences. Cure of infection determined an evident improvement of corporal atrophy as well as a reduction of hypergastrinemia.
Active H. pylori infection, a potential cause of oxyntic gland atrophy, is found in one-fourth of patients with newly diagnosed atrophic body gastritis.
通常,萎缩性胃体炎被认为是一种以壁细胞抗体存在为特征的自身免疫性疾病。先前关于幽门螺杆菌感染作用的研究结果相互矛盾。本研究的目的是调查幽门螺杆菌在一项前瞻性研究的以胃体为主的萎缩性胃炎患者群体中的患病率及作用。
连续67例新诊断的萎缩性胃体炎病例来自对326例不明原因贫血或消化不良患者的筛查。诊断标准为空腹高胃泌素血症、对五肽胃泌素无反应的无酸血症以及胃体萎缩的组织学证实。在所有67例患者中,通过组织学检测和尿素酶试验独立评估幽门螺杆菌感染情况。根据悉尼系统对胃底和胃窦黏膜的胃炎状态进行分级。还测定了壁细胞抗体和内因子抗体。
26.8%的患者存在活动性幽门螺杆菌感染,这使我们能够识别出一个患者亚群,其胃体黏膜损伤程度明显较小,这在功能参数(胃泌素、胃酸分泌、胃蛋白酶原I)和组织学评估中均有体现。在这个亚群中,发现胃癌家族史的患病率较高。壁细胞抗体在幽门螺杆菌阳性和阴性患者中的患病率相似(61.1%对69.4%),且与显著的功能和组织学差异无关。感染治愈后,胃体萎缩明显改善,高胃泌素血症也有所降低。
活动性幽门螺杆菌感染是胃底腺萎缩的一个潜在原因,在新诊断的萎缩性胃体炎患者中,有四分之一的患者存在该感染。